Rheumatoid Arthritis

      A#1743
      Are there benefits of getting LDA to remission?
      Remission CDAI <2.8, VLDA 2.8-6, LDA 6-10
      After 1 yr f/u of LD

      Eric Dein ericdeinmd

      11 months 1 week ago
      A#1743 Are there benefits of getting LDA to remission? Remission CDAI <2.8, VLDA 2.8-6, LDA 6-10 After 1 yr f/u of LDA, 45% Rem, 40 VLDA, 16 LDA Not in remiss - higher BMI, longer duration, higher resource utilization, worse PRO No clear diff bw remission & VLDA #ACR24 @RheumNow https://t.co/ut7c52JVDr
      Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0

      Richard Conway RichardPAConway

      11 months 1 week ago
      Frideres et al. Target trial emulation in RA-ILD. Primar outcome death or respiratory hospitialization. Abatacept (aHR 0.90), tocizilumab (aHR 0.93), tofacitinib (aHR 0.69) vs rituximab. @RheumNow #ACR24 Abstr#1713 https://t.co/fbE8xAnzQ2 https://t.co/uwzH8oAyAT
      A#1694
      To get one or two lungs for lung transplant? 🫁

      Autoimmune related ILD transplant outcomes?
      145 single (SLT),

      Eric Dein ericdeinmd

      11 months 1 week ago
      A#1694 To get one or two lungs for lung transplant? 🫁 Autoimmune related ILD transplant outcomes? 145 single (SLT), 461 double (DLT) Similar 1 yr mortality - HR SLT 1.19 unadjusted, 1.49 adj - not statistically significance @RheumNow #ACR24 https://t.co/uo8WbrNFAm
      A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop

      sheila RHEUMarampa

      11 months 1 week ago
      A retrospective analysis by Dr. ERayens et al showed that RA pts >/=50y given 2 RZV doses were less likely to develop HZ vs. unvaxxed grp Incidence of PHN was also lower in the vaccinated group (0.2py vs.1.9py) RZV is effective in preventing HZ & PhN @Rheumnow #ACR25 abs0977 https://t.co/JhYBYnLmhl
      2023 @ACRheum guidance recommends #MediterraneanDiet in RA

      What are barriers/facilitators to following the diet?

      Many

      Mrinalini Dey DrMiniDey

      11 months 1 week ago
      2023 @ACRheum guidance recommends #MediterraneanDiet in RA What are barriers/facilitators to following the diet? Many pts are willing to try but don't follow it Barriers➡️ food insecurity & aversions Many are unaware Do you talk to your pts about diet? Ab1673 #ACR24 @RheumNow
      RA-ILD:
      💡Lifetime prevalence seems low but ~40% can have subclincal.
      💡Screen early in symptomatic pts.
      💡RA dise

      Adela Castro AdelaCastro222

      11 months 1 week ago
      RA-ILD: 💡Lifetime prevalence seems low but ~40% can have subclincal. 💡Screen early in symptomatic pts. 💡RA disease control decreases ILD progression and mortality. 💡RA-ILD UIP pattern seems to respond to immunosuppression. #ACR24 @RheumNow https://t.co/q3iACMeYVU
      Subgroup data from SELECT GCA, overall reinforces overall message

      I was curious to see pts previously treated with TCZ;

      Mike Putman EBRheum

      11 months 1 week ago
      Subgroup data from SELECT GCA, overall reinforces overall message I was curious to see pts previously treated with TCZ; wonder if that selects for refractory phenotype - seems not to be the case Take home: encouraging data, no subgroup issues #ACR24 @RheumNow Abstr#1695 https://t.co/5iCLE6T4u3
      This will change my practice!
      #RCT #MMF + #MTX
      superior to
      #Cyclophosphamide then #Azathioprine

      In
      #Tayakasu’s #ar

      Janet Pope Janetbirdope

      11 months 1 week ago
      This will change my practice! #RCT #MMF + #MTX superior to #Cyclophosphamide then #Azathioprine In #Tayakasu’s #arteritis N=150 RCT ~1g BID #mycophenolate + 15mg/wk #Methotrexate Vs #cyclo ➡️100mg #azathioprine All got #glucocorticoids #ACR24 @RheumNow @ACRheum #1696 https://t.co/OpRep1vsmx
      Very neat simulated model of GC regimens in AAV pt on fixed RTX by @zach_wallace_md and co

      Over 5 years:
      - No differe

      Brian Jaros, MD Dr_Brian_MD

      11 months 1 week ago
      Very neat simulated model of GC regimens in AAV pt on fixed RTX by @zach_wallace_md and co Over 5 years: - No difference in relapse btwn standard GC vs. minimal GC + avacopan - Higher DMII rates in standard group Adds to trial + real world data @RheumNow #ACR24 Abst 1598
      Alright help me out here; this is pretty implausible, right?

      Why would be pts be 11% more adherent to UPA? What's the

      Mike Putman EBRheum

      11 months 1 week ago
      Alright help me out here; this is pretty implausible, right? Why would be pts be 11% more adherent to UPA? What's the bio-plausibility here? UPA 10% better than other JAKs? Could do a network meta analysis; betting this doens't replicate #ACR24 @RheumNow Abstr#1362 https://t.co/vpPq3vu9Wf
      #Rheumatoid #arthritis is an independent risk factor for death in nonmetastatic clear cell renal ca !

      👇N=32K, 802 w

      Janet Pope Janetbirdope

      11 months 1 week ago
      #Rheumatoid #arthritis is an independent risk factor for death in nonmetastatic clear cell renal ca ! 👇N=32K, 802 w RA also Caveats immunotherapy Offered = in RA Cancer specific mortality not affected By #RA Frailty & RA affected outcomes #ACR24 @RheumNow @ACRheum #1327 https://t.co/rAQ57BPA19
      In this large 🇦🇺 RA cohort, median time on treatment for upadacitinib was lot higher than other JAKi
      (28mo vs 17mo

      David Liew drdavidliew

      11 months 1 week ago
      In this large 🇦🇺 RA cohort, median time on treatment for upadacitinib was lot higher than other JAKi (28mo vs 17mo) Why? Patient selection, or a real difference between JAKi? Would really like more comparative effectiveness data between JAKi #ACR24 OPAL group ABST1370 @RheumNow https://t.co/OU2ayzqIc8
      Spicy network SRMA, 123pts w/JAK-TNF-PLBO

      TNF >> JAK w/respect to malignancy (expected) & better than PLBO (s

      Mike Putman EBRheum

      11 months 1 week ago
      Spicy network SRMA, 123pts w/JAK-TNF-PLBO TNF >> JAK w/respect to malignancy (expected) & better than PLBO (spicy!) JAK > PLBO for heme cancers (makes sense); no significant (but slight trend) toward PLBO > JAK for all cancer The debate continues #ACR24 @RheumNow Abstr#0989 https://t.co/tBnb02gyzF
      Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter?

      in the upadacitinib ph3 t

      David Liew drdavidliew

      11 months 1 week ago
      Which RA patients are at increased risk of JAKi adverse events? Does disease activity matter? in the upadacitinib ph3 trials, high disease activity pts had more: serious infections HZ MACE VTE Active RA is a massive contributor to many AEs in JAKi pts #ACR24 ABST1393 @RheumNow https://t.co/DlFf9Sfbja
      Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in met

      Richard Conway RichardPAConway

      11 months 1 week ago
      Zhang @jeffsparks et al. Even more evidence that MTX does not cause ILD, and in fact prevents ILD, in RA, OR 0.48 in meta-analysis. @RheumNow #ACR24 Abstr#1384 https://t.co/YvQnmmvNjF https://t.co/crYUwHahDb

      Catch up on Conference Podcasts

      ×